Financial Snapshot

Revenue
$715.2M
TTM
Gross Margin
86.51%
TTM
Net Earnings
-$250.1M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
436.0%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$237.1M
Q3 2024
Cash
Q3 2024
P/E
-16.98
Nov 29, 2024 EST
Free Cash Flow
-$205.6M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Revenue $396.6M $75.42M $66.56M $250.6M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change 425.83% 13.31% -73.44%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Revenue $396.6M $75.42M $66.56M $250.6M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue $58.51M $5.636M $5.200M $25.10M
Gross Profit $338.1M $69.79M $61.36M $225.6M
Gross Profit Margin 85.25% 92.53% 92.19% 90.01%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Selling, General & Admin $500.8M $277.2M $284.5M $215.7M $67.00M $22.60M $10.50M $4.300M $6.400M $2.900M $1.700M
YoY Change 80.69% -2.56% 31.87% 221.94% 196.46% 115.24% 144.19% -32.81% 120.69% 70.59%
% of Gross Profit 148.13% 397.16% 463.55% 95.61%
Research & Development $354.4M $387.2M $345.9M $299.9M $221.0M $105.3M $40.30M $22.98M $13.73M $8.400M $2.300M
YoY Change -8.48% 11.96% 15.32% 35.73% 109.88% 161.23% 75.4% 67.36% 63.46% 265.22%
% of Gross Profit 104.82% 554.89% 563.64% 132.94%
Depreciation & Amortization $1.784M $1.552M $1.379M $637.0K $240.0K $10.00K $10.00K
YoY Change 14.95% 12.55% 116.48% 165.42% 0.0%
% of Gross Profit 0.53% 2.22% 2.25% 0.28%
Operating Expenses $913.7M $670.0M $602.8M $464.4M $288.0M $127.9M $40.30M $22.98M $13.73M $11.30M $4.000M
YoY Change 36.37% 11.15% 29.82% 61.23% 125.14% 217.4% 75.4% 67.36% 21.51% 182.5%
Operating Profit -$517.1M -$594.6M -$536.3M -$213.7M -$288.0M -$127.9M -$50.77M -$27.28M -$46.57M
YoY Change -13.03% 10.88% 150.92% -25.79% 125.14% 151.98% 86.08% -41.42%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Interest Expense -$8.648M -$23.71M -$110.5M -$128.8M -$15.00M $500.0K -$96.92K $135.3K $50.85K
YoY Change -63.53% -78.54% -14.21% 758.67% -3100.0% -615.92% -171.62% 166.08%
% of Operating Profit
Other Income/Expense, Net -$727.0K -$288.0K $1.362M -$501.0K -$175.0K -$25.00K -$142.2K $22.40K $100.0K $100.0K $100.0K
YoY Change 152.43% -121.15% -371.86% 186.29% 600.0% -82.41% -734.71% -77.6% 0.0% 0.0%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Pretax Income -$526.5M -$651.5M -$746.0M -$343.0M -$304.7M -$127.5M -$47.52M -$27.10M -$46.50M -$11.20M -$4.000M
YoY Change -19.19% -12.67% 117.47% 12.58% 138.98% 168.29% 75.36% -41.72% 315.18% 180.0%
Income Tax $2.132M $669.0K $352.0K $1.845M $0.00 $0.00 $0.00 $0.00 -$400.0K $0.00
% Of Pretax Income
Net Earnings -$528.6M -$652.2M -$746.4M -$344.9M -$304.7M -$127.5M -$51.01M -$27.12M -$46.50M -$10.80M -$4.000M
YoY Change -18.94% -12.62% 116.41% 13.18% 138.98% 149.97% 88.04% -41.67% 330.56% 170.0%
Net Earnings / Revenue -133.29% -864.7% -1121.27% -137.59%
Basic Earnings Per Share -$4.45 -$6.15 -$8.84 -$4.59
Diluted Earnings Per Share -$4.45 -$6.15 -$8.841M -$4.586M -$4.899M -$2.344M -$1.034M -$549.7K -$943.2K -$219.1K -$81.14K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Cash & Short-Term Investments $351.2M $551.8M $700.6M $877.6M $352.0M $176.3M $175.6M $24.90M $36.00M $13.60M $4.800M
YoY Change -36.36% -21.23% -20.17% 149.32% 99.66% 0.4% 605.22% -30.83% 164.71% 183.33%
Cash & Equivalents $351.2M $551.8M $640.2M $565.8M $352.0M $176.3M $175.6M $24.90M $36.00M $13.60M $4.800M
Short-Term Investments $0.00 $60.36M $311.9M
Other Short-Term Assets $44.29M $52.84M $97.11M $39.50M $21.10M $24.70M $5.100M $1.200M $300.0K $100.0K $300.0K
YoY Change -16.18% -45.59% 145.84% 87.2% -14.57% 384.31% 325.0% 300.0% 200.0% -66.67%
Inventory $146.4M $85.71M $16.29M
Prepaid Expenses
Receivables $206.4M $7.727M $10.10M
Other Receivables $18.05M $21.44M $0.00
Total Short-Term Assets $766.3M $719.5M $824.0M $917.2M $373.1M $202.4M $182.0M $27.40M $38.00M $14.20M $5.200M
YoY Change 6.51% -12.68% -10.16% 145.83% 84.34% 11.21% 564.23% -27.89% 167.61% 173.08%
Property, Plant & Equipment $21.09M $24.90M $26.08M $24.50M $15.80M $0.00 $0.00
YoY Change -15.28% -4.54% 6.44% 55.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.309M $15.80M $31.64M $18.90M $400.0K $1.100M $100.0K $100.0K $100.0K $0.00 $0.00
YoY Change -91.71% -50.07% 67.41% 4625.0% -63.64% 1000.0% 0.0% 0.0%
Total Long-Term Assets $22.40M $40.69M $57.72M $43.40M $16.10M $1.100M $100.0K $0.00 $200.0K $100.0K $0.00
YoY Change -44.96% -29.5% 32.99% 169.57% 1363.64% 1000.0% -100.0% 100.0%
Total Assets $788.7M $760.2M $881.8M $960.6M $389.2M $203.5M $182.1M $27.40M $38.20M $14.30M $5.200M
YoY Change
Accounts Payable $37.52M $37.34M $16.91M $8.500M $8.400M $10.30M $3.700M $2.500M $2.500M $800.0K $400.0K
YoY Change 0.47% 120.84% 98.93% 1.19% -18.45% 178.38% 48.0% 0.0% 212.5% 100.0%
Accrued Expenses $134.2M $100.8M $107.4M $115.6M $57.40M $5.100M $2.900M $1.100M $700.0K $300.0K $300.0K
YoY Change 33.23% -6.14% -7.13% 101.39% 1025.49% 75.86% 163.64% 57.14% 133.33% 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $75.83M $29.50M $7.584M $4.200M $1.700M
YoY Change 157.02% 289.03% 80.57%
Total Short-Term Liabilities $247.6M $167.6M $131.8M $128.3M $65.80M $17.00M $6.600M $3.600M $3.200M $1.100M $700.0K
YoY Change 47.72% 27.12% 2.76% 94.98% 287.06% 157.58% 83.33% 12.5% 190.91% 57.14%
Long-Term Debt $332.9M $408.4M $534.2M $358.8M $142.6M $25.40M $26.40M $0.00 $0.00 $0.00 $0.00
YoY Change -18.5% -23.55% 48.88% 151.61% 461.42% -3.79%
Other Long-Term Liabilities $13.77M $14.35M $17.08M $268.9M $146.7M $200.0K $200.0K
YoY Change -4.08% -15.98% -93.65% 83.3% 73250.0% 0.0%
Total Long-Term Liabilities $346.6M $422.7M $551.3M $627.7M $289.3M $25.60M $26.60M $0.00 $0.00 $0.00 $0.00
YoY Change -18.01% -23.31% -12.18% 116.97% 1030.08% -3.76%
Total Liabilities $594.2M $590.3M $683.1M $756.0M $355.0M $42.60M $33.20M $3.600M $3.200M $1.100M $700.0K
YoY Change 0.65% -13.58% -9.64% 112.96% 733.33% 28.31% 822.22% 12.5% 190.91% 57.14%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Basic Shares Outstanding 118.7M 106.1M 84.42M 75.16M
Diluted Shares Outstanding 118.7M 106.1M 84.42M 75.16M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $4.2455 Billion

About Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. The company is headquartered in Waltham, Massachusetts and currently employs 702 full-time employees. The company went IPO on 2017-11-09. The firm is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.

Industry: Pharmaceutical Preparations Peers: Sarepta Therapeutics, Inc. Biohaven Pharmaceutical Holding Co Ltd. IONIS PHARMACEUTICALS INC Karuna Therapeutics, Inc. Legend Biotech Corp NEUROCRINE BIOSCIENCES INC UNITED THERAPEUTICS Corp